FATE THERAPEUTICS INC (FATE) Financials
Annual revenue, profitability and per-share results for FATE THERAPEUTICS INC, as reported in SEC filings.
Revenue • FY2025
$6.65M
▼ 51.2%YoY
Net income • FY2025
-$136.31M
▲ 26.8%YoY
Diluted EPS • FY2025
-$1.15
▲ 29.9%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $6.65M | -$136.31M | — | -$1.15 | -$112.04M | -2222.4% | -51.2% |
| FY2024 | $13.63M | -$186.26M | — | -$1.64 | -$123.6M | -1542.6% | -78.5% |
| FY2023 | $63.53M | -$160.93M | — | -$1.64 | -$138.42M | -299.9% | -34.0% |
| FY2022 | $96.3M | -$281.72M | — | -$2.91 | -$283.77M | -320.2% | +72.4% |
Figures as reported in FATE THERAPEUTICS INC's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a FATE filing.
Get an email when FATE files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.